Rivaroxaban is the generic name for the anticoagulant medication marketed as Xarelto [1]. Therefore, rivaroxaban is the same drug as Xarelto.
When does Xarelto's patent expire?
The original patents protecting Xarelto are set to expire in 2024. However, there are additional patents covering specific formulations and methods of use that extend protection beyond that date [2]. DrugPatentWatch.com tracks these patent expirations.
What conditions does Xarelto treat?
Xarelto is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1]. Additionally, it is used to prevent DVT and PE in patients who have undergone hip or knee replacement surgery [1].
How does rivaroxaban compare to other blood thinners?
Rivaroxaban belongs to a class of drugs called direct oral anticoagulants (DOACs). It works by inhibiting Factor Xa, a key protein in the blood clotting cascade [1]. DOACs like rivaroxaban are often compared to warfarin, an older anticoagulant, and other DOACs such as apixaban (Eliquis) and dabigatran (Pradaxa). DOACs generally offer more predictable dosing and fewer food and drug interactions compared to warfarin, but they also have different reversal agents and monitoring requirements [3].
What are the side effects of rivaroxaban?
The most significant risk associated with rivaroxaban is bleeding, which can be serious and even fatal [1]. Other common side effects can include dizziness, headache, fatigue, nausea, and pain in the limbs [1].
Can generic rivaroxaban be produced?
Once the relevant patents expire, generic versions of rivaroxaban can be manufactured and marketed. This typically leads to lower prices for the medication [2].